Simplex Trading’s Cardiol Therapeutics CRDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$47K Buy
+34,800
New +$35.7K ﹤0.01% 5948
2025
Q3
Sell
-79,000
Closed -$107K 9195
2025
Q2
$107K Sell
79,000
-43,800
-36% -$51K ﹤0.01% 5164
2025
Q1
$119K Sell
122,800
-19,900
-14% -$24.4K ﹤0.01% 4880
2024
Q4
$182K Buy
142,700
+91,300
+178% +$154K ﹤0.01% 4607
2024
Q3
$101K Sell
51,400
-219,000
-81% -$454K ﹤0.01% 5219
2024
Q2
$546K Buy
270,400
+188,600
+231% +$400K ﹤0.01% 3574
2024
Q1
$148K Buy
81,800
+56,800
+227% +$76.6K ﹤0.01% 5168
2023
Q4
$21K Buy
+25,000
New +$21.2K ﹤0.01% 6876
2023
Q1
Sell
-39,400
Closed -$20K 9162
2022
Q4
$20K Sell
39,400
-97,900
-71% -$59.7K ﹤0.01% 6861
2022
Q3
$141K Buy
137,300
+127,800
+1,345% +$156K ﹤0.01% 5054
2022
Q2
$12K Sell
9,500
-323,300
-97% -$460K ﹤0.01% 8111
2022
Q1
$509K Sell
332,800
-42,600
-11% -$70.3K ﹤0.01% 3817
2021
Q4
$694K Buy
+375,400
New +$1.04M ﹤0.01% 3371

Other funds holding CRDL

Simplex Trading's CRDL Position: Q1 2026 in Review

Simplex Trading sold out of Cardiol Therapeutics (CRDL) in Q1 2026, closing a stake of 32,197 shares — an estimated $33K sold.

Simplex Trading first reported a position in CRDL in Q1 2022 and held it in 6 quarters. The position peaked at $37K in Q1 2022. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Simplex Trading reported no remaining Cardiol Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 32,197 Cardiol Therapeutics shares in Q1 2026, an estimated $33K.
  • Simplex Trading first reported a position in Cardiol Therapeutics in Q1 2022 and held it in 6 quarters.
  • Simplex Trading's Cardiol Therapeutics position peaked at $37K in Q1 2022.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.